Lab No. : KHA/13-11-2024/SR9900929 Lab Add.

: Newtown,Kolkata-700156

Patient Name : SUBRATA KUNDU Ref Dr. : Dr.PARTHA SARATHI AIN

Age : 41 Y 9 M 25 D Collection Date : 13/Nov/2024 10:35AM

Gender :M Report Date : 13/Nov/2024 04:24PM

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Bio Ref. Interval Unit

URIC ACID,BLOOD , GEL SERUM 6.5 3.5-7.2 mg/dL

(Method:Uricase/Peroxidase)

25-HYDROXY VITAMIN D - TOTAL 47.71 ***FOR BIOLOGICAL REFERENCE ng/mL

(Method:CLIA) INTERVAL DETAILS , PLEASE
REFER TO THE BELOW
MENTIONED REMARKS/NOTE
WITH ADDITIONAL CLINICAL
INFORMATION ***

Biological Reference Intervals :

<20 ng/mL (deficiency)*
20-30 ng/mL (insufficient)**
30-100 ng/mL (optimum levels)***
>100 ng/mL (toxicity possible)****

* Could be associated with osteomalacia/ rickets

** May be associated with increased risk of osteoporosis or secondary hyperparathyroidism
*** Optimum levels in the normal population
**** 80 ng/mL is the lowest reported level associated with toxicity in patients without primary hyperparathyroidism who have normal renal function. Most
patients with toxicity have levels >150 ng/mL. Patients with renal failure can have very high 25-OH-VitD levels without any signs of toxicity, as renal
conversion to the active hormone 1,25-OH-VitD is impaired or absent.
These reference ranges represent clinical decision values that apply to males and females of all ages, rather than population-based reference values.
Population reference ranges for 25-OH-VitD vary widely depending on ethnic background, age, geographic location of the studied populations, and the
sampling-season. Population-based ranges correlate poorly with serum 25-OH-VitD concentrations that are associated with biologically and clinically
relevant vitamin D effects and are therefore of limited clinical value.

Clinical References :
1.Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357:266-81.
2. Jones G, Strugnell SA, DeLuca HF: Current understanding of the molecular actions of vitamin D. Physiol Rev 1998 Oct;78(4):1193-1231.
3. Miller WL, Portale AA: Genetic causes of rickets. Curr Opin Pediatr 1999 Aug;11(4):333-339
4. Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999 May;69(5):842-856.

INSULIN,FASTING 4.5 3.5 -25.0 µU/mL µU/mL

(Method:CLIA)

GLUCOSE,FASTING 86 Impaired Fasting-100-125 mg/dL

(Method:Gluc Oxidase Trinder) .~Diabetes- >= 126.~Fasting is
defined as no caloric intake for at
least 8 hours.

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference :
ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

*** End Of Report ***

Page 1 of 4
 Lab No. : KHA/13-11-2024/SR9900929 Lab Add. : Newtown,Kolkata-700156

Patient Name : SUBRATA KUNDU Ref Dr. : Dr.PARTHA SARATHI AIN

Age : 41 Y 9 M 25 D Collection Date : 13/Nov/2024 10:35AM

Gender :M Report Date : 13/Nov/2024 04:24PM

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Bio Ref. Interval Unit

Lab No. : KHA/13-11-2024/SR9900929 Page 2 of 4

 Lab No. : KHA/13-11-2024/SR9900929 Lab Add. : Newtown,Kolkata-700156

Patient Name : SUBRATA KUNDU Ref Dr. : Dr.PARTHA SARATHI AIN

Age : 41 Y 9 M 25 D Collection Date : 13/Nov/2024 10:41AM

Gender :M Report Date : 13/Nov/2024 05:16PM

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Bio Ref. Interval Unit

GLYCATED HAEMOGLOBIN (HBA1C) , EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 5.9 ***FOR BIOLOGICAL REFERENCE %
INTERVAL DETAILS , PLEASE
REFER TO THE BELOW
MENTIONED REMARKS/NOTE
WITH ADDITIONAL CLINICAL
INFORMATION ***
HbA1c (IFCC) 41 mmol/mol
(Method:HPLC)

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC)
Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC)
Diabetics-HbA1c level : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

Analyzer used :- Bio-Rad-VARIANT TURBO 2.0

Method : HPLC Cation Exchange

Recommendations for glycemic targets

Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular
disease . Action suggested >8% as it indicates poor control.
Ø Some patients may benefit from HbA1c goals that are stringent.
Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after
surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B12/ folate deficiency, presence of chronic renal or liver
disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.
Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8
References:
1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published
online 1 March 2016. doi:10.7326/M15-3016.
2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC
Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

PDF Attached
LIPID PROFILE , GEL SERUM
CHOLESTEROL-TOTAL 229 Desirable: < 200 mg/dL mg/dL
(Method:Enzymatic) Borderline high: 200-239 mg/dL
High: > or =240 mg/dL
TRIGLYCERIDES 162 Normal:: < 150, mg/dL
(Method:GPO-Trinder) BorderlineHigh::150-199,
High:: 200-499,
VeryHigh::>500
HDL CHOLESTEROL 46 < 40 - Low mg/dl
(Method:Elimination/catalase) 40-59- Optimum
60 - High
LDL CHOLESTEROL DIRECT 169 OPTIMAL : <100 mg/dL, mg/dL
(Method:Elimination / Catalase) Near optimal/ above optimal : 100-
129 mg/dL,
Borderline high : 130-159 mg/dL,
High : 160-189 mg/dL,
Very high : >=190 mg/dL
VLDL 14 < 40 mg/dl mg/dl
Lab No. : KHA/13-11-2024/SR9900929 Page 3 of 4
 Lab No. : KHA/13-11-2024/SR9900929 Lab Add. : Newtown,Kolkata-700156

Patient Name : SUBRATA KUNDU Ref Dr. : Dr.PARTHA SARATHI AIN

Age : 41 Y 9 M 25 D Collection Date : 13/Nov/2024 10:41AM

Gender :M Report Date : 13/Nov/2024 05:16PM

DEPARTMENT OF BIOCHEMISTRY
Test Name Result Bio Ref. Interval Unit

(Method:Calculated)
CHOL HDL Ratio 5 LOW RISK 3.3-4.4 AVERAGE RISK
(Method:Calculated) 4.47-7.1 MODERATE RISK 7.1-11.0
HIGH RISK >11.0

Reference: National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP)
Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-
97.

LIVER FUNCTION TEST , GEL SERUM

BILIRUBIN (TOTAL) 0.6 0.3-1.2 mg/dL
(Method:Vanadate oxidation)
BILIRUBIN (DIRECT) 0.1 <0.2 mg/dL
(Method:Vanadate oxidation)
BILIRUBIN (INDIRECT) 0.5 0.0 - 0.9 mg/dl
(Method:Calculated)
SGPT/ALT 44 7-40 U/L
(Method:Modified IFCC)
SGOT/AST 28 13-40 U/L
(Method:Modified IFCC)
ALKALINE PHOSPHATASE 94 46-116 U/L
(Method:IFCC standardization )
TOTAL PROTEIN 7.6 5.7-8.2 g/dL g/dL
(Method:BIURET METHOD)
ALBUMIN,BLOOD 4.9 3.2-4.8 g/dL
(Method:BCG Dye Binding)
GLOBULIN 2.7 1.8-3.2 g/dl
(Method:Calculated)
AG Ratio 1.81 1.0-2.5
(Method:Calculated)

Lab No. : KHA/13-11-2024/SR9900929 Page 4 of 4

SURAKSHA DIAGNOSTIC,RAJARHAT,KOLKATA PATIENT REPORT
BIO-RAD VARIANT-II TURBO CDM5.4. SN-16122 V2TURBO_A1c_2.0

Patient Data Analysis Data

Sample ID: E02132968769 Analysis Performed: 13/NOV/2024 16:54:43
Patient ID: SR9900929 Injection Number: 877U
Name: Run Number: 12
Physician: Rack ID: 0007
Sex: Tube Number: 1
DOB: Report Generated: 13/NOV/2024 17:10:29
Operator ID: PAYEL
Comments:

NGSP Retention Peak

Peak Name % Area % Time (min) Area
A1a --- 1.4 0.167 29406
A1b --- 1.9 0.240 40623
LA1c --- 1.9 0.425 40477
A1c 5.9 --- 0.537 108230
P3 --- 3.9 0.811 83856
P4 --- 1.5 0.882 31285
Ao --- 84.3 1.026 1790332

Total Area: 2,124,210

HbA1c (NGSP) = 5.9 % HbA1c (IFCC) = 41 mmol/mol

20.0

17.5

15.0

12.5
%A1c

10.0
0.54

0.81

7.5
A1c -

0.88
-
0.24

0.43
0.17

5.0
-
-

-
-

2.5
1.03

0.0
-

0.00 0.25 0.50 0.75 1.00 1.25 1.50

Time (min.)